Abstract: The significance and clinical management of Candida colonization of the respiratory tract are ill-defined. We now report the frequency of Candida species from the lower respiratory tract in hematopoietic stem cell transplant recipients (HSCT) undergoing bronchoscopy with broncheoalveolar lavage for pneumonitis after HSCT. The University of Michigan Clinical Microbiology Laboratory Database was queried for all respiratory cultures positive for Candida species between 2000 and 2012. We concurrently performed a retrospective analysis of 515 HSCT recipients with pneumonitis at our institution between 2001 and 2012. During this 12-year period, there were 2524 unique Candida isolates (78% Candida albicans). Of the 515 HSCT patients with suspected pneumonitis, 127 (24.7%) HSCT subjects were culture positive for a fungal pathogen, with Candida species identified in 27 cases (5.2%). When compared with other HSCT subjects, those cultures positive for Candida had significantly increased mortality (P = 0.04). Candida sp. are commonly cultured from the respiratory tract of HSCT recipients, with increased mortality in affected patients. While there is insufficient evidence for antifungal treatment of Candida species colonization, the presence of the yeast may be useful as a surrogate marker of disease severity.
C andida pneumonia in immunocompetent and immunocompromised patients is rare [1] [2] [3] ; however, we propose that the clinical implications of Candida isolation from the respiratory tract, particularly in immunodeficient patients, should not be underestimated with regard to increased morbidity or mortality in this particular population. The fungus Candida albicans is considered a member of the normal human oral and gastrointestinal microbiome; however, lower respiratory tract colonization in mechanically ventilated immunocompetent patients has been independently associated with longer duration of mechanical ventilation, increased risk of ventilator-associated pneumonia (VAP), and increased length of intensive care unit (ICU) and hospital stay. [4] [5] [6] A small prospective study of immunocompromised patients found increased mortality in patients with respiratory tract colonization. 7 We now show, in one of the largest retrospective studies to date of hematopoietic stem cell transplant (HSCT) patients, that Candida colonization of the airway is associated with worse outcomes.
METHODS
We queried the University of Michigan Clinical Microbiology Lab Database for all respiratory cultures positive for Candida species between 2000 and 2012 (University of Michigan IRB HUM00105276). Respiratory cultures reviewed included those from sputum, broncheoalveolar lavage (BAL) fluid, bronchial brushings, washings and biopsies, endotracheal aspirates, and pleural fluid, as well as swabs from the mouth, oropharynx, pharynx, or sinuses. Many centers consider C. albicans as "normal oral flora" and do not report it in hospital microbiology cultures for immunocompetent patients unless specifically requested.
We then studied a cohort of 515 HSCT recipients at the University of Michigan between 2001 and 2012, who had radiographic or clinical evidence of pulmonary dysfunction after transplant, and underwent bronchoscopy with BAL, as clinically indicated for their care (IRB HUM00046894; IRBMED 2001-0234). Subjects were followed-up for their lifetime, until withdrawal from the study, or until lost to follow-up. Pre-HSCT treatment-conditioning chemotherapy, stem cell source, and donor selection, were administered according to current HSCT guidelines. Unless contraindicated, all transplant recipients received antifungal prophylaxis (fluconazole or voriconazole) and antiviral prophylaxis according to our center's clinical practice guidelines. Antifungal and antibacterial prophylaxes were given for 100 days after transplant in allogeneic transplant recipients and until engraftment in autologous recipients. Antiviral prophylaxis was given for 1 year following transplant in all recipients. All allogeneic transplant recipients additionally received prophylaxis against graft versus host disease (GVHD).
Statistical analyses were performed using χ 2 , Fisher exact, 1-way analysis of variance, and Kruskal-Wallis measurements. Kaplan-Meier survival curves were used for all survival analyses with log-rank P-values reported. Data were analyzed using GraphPad Prism 7 (San Diego, CA). The statistically significant difference between groups was assessed at the level of P < 0.05.
RESULTS
Over a 12-year period, 2346 respiratory specimens grew Candida species, representing 2524 unique Candida isolates. Just under half of all cultures (40.7%) were obtained from sputum or endotracheal aspirate, 23.7% were bronchoscopically obtained, and 17.1% were from the oral cavity. The remaining 20% was comprised of cultures from pleural, nasal, and sinus sources. C. albicans (78%) was the most prevalent species, independent of method of collection, followed by Candida glabrata (11%). No other species of Candida comprised > 5% of isolates. A total of 178 specimens (7.6%) grew 2 or more distinct morphologies or different species of Candida. Co-colonization with pathogenic bacteria (7.7%) or fungi (2.3%) was infrequent. Thus, we found that Candida species are commonly isolated from respiratory specimens of our hospitalized patients, with C. albicans accounting for over 75% of the isolates.
The HSCT cohort included 331 male and 184 female patients, of whom 81% had undergone allogeneic (45.1% related donor; 54.9% unrelated donor) and 19% had undergone autologous transplants. The mean age at the time of transplant was 44.25 years (range: 2 mo to 75 y; SD = 19.95). The most frequent indications for HSCT were acute myeloid leukemia (22.7%), non-Hodgkins lymphoma (20.4%), and multiple myeloma (10.3%). Additional characteristics of the study group are shown in Table 1 . All but 2 of the patients were followed-up for > 1year after bronchoscopy.
We found that 142/515 (27.6%) HSCT subjects had BAL cultures positive for any fungus, with Candida representing 27 cases (5.2% overall). The most commonly isolated species was C. albicans, followed by C. glabrata. Candida species were coisolated with a pathogenic fungus such as Aspergillus or Pneumocystis in only 4/27 cases. Autologous transplant recipients were significantly more likely than allogeneic transplant recipients to be culture positive for Candida in the first 100 days following transplant (75% vs. 21%; P = 0.008). As previously stated, all HSCT patients received antifungal prophylaxis with fluconazole or voriconazole, unless contraindicated for 100 days or until engraftment. A total of 5/27 subjects with Candida on BAL received new or additional treatment dose antifungal therapy for at least 24 hours before undergoing bronchoscopy. In this Candida-positive group, 12/27 patients had known or highly suspected GVHD at the time of bronchoscopy. Concurrent transbronchial biopsies were obtained in 6/27 patients. Neither Candida species nor evidence of invasive fungal pneumonia were histologically present on any of the biopsies. One returned with findings consistent with GVHD.
For our subsequent analyses, we divided the cohort into 4 groups according to BAL culture results: Candida isolated (n = 27), nonpathogenic fungi isolated (Candida negative) (n = 57), pathogenic fungi isolated (n = 58), or fungal-negative pneumonitis (n = 373). The distinction between pathogenic and nonpathogenic fungi was arbitrated by a transplant infectious disease physician ( Table 2 ). The group with "fungal-negative pneumonitis" was defined as having BAL cultures free from any fungal growth but inclusive of cultures positive for viral or bacterial pathogens, as well as sterile cultures. There were no differences in 3-year survival between subjects who grew any pathogenic or nonpathogenic fungi in their BAL when compared with those who had "fungal-negative pneumonitis" (P = 0.45). In contrast, those who had Candida isolated from their BAL had significantly increased 3-year mortality when compared with patients who had other classically defined "nonpathogenic fungi" (P = 0.04; Fig. 1A ). When compared with the "fungal-negative pneumonitis" group, those with Candida showed a trend toward increased mortality (P = 0.06). There was no statistical difference in 3-year mortality between subjects who had BAL fluid cultures positive for pathogenic fungi and those in whom Candida species were cultured (P = 0.24; Fig. 1B ).
DISCUSSION
To our knowledge, this is the first study to characterize the frequency of Candida colonization in the respiratory tract of a heterogenous population of immunocompromised patients. Asymptomatic colonization of Candida in the oropharynx is estimated to occur in 20% to 50% of healthy individuals, with even higher rates seen in hospitalized and immunocompromised patients. [8] [9] [10] While Candida may be frequently isolated from the respiratory tract, it has been well established that true invasive Candida pneumonia is a rare phenomenon in both immunocompetent and immunocompromised patients. 1,2,11-13 These studies, primarily postmortem in nature, have shown a poor correlation between positive respiratory cultures and positive histology for invasive Candida infection. Consequently, current guidelines do not recommend treatment of respiratory tract Candida with antifungal drugs. Even so, a great deal of clinical uncertainty remains in how to handle respiratory isolation of Candida. In one study, a quarter of ICU physicians stated they would prescribe antifungal therapy for an immunocompetent ICU patient with respiratory Candida isolated; the same physicians stated they would be even more aggressive in treating an immunocompromised patient. 14 Currently, there is no test or threshold able to distinguish between sampling artifact, colonization, or true infection, forcing the clinician to make decisions using clinical judgment.
Recently, a number of animal and human studies have suggested that Candida colonization of the respiratory tract, while not directly pathogenic, may contribute to worse outcomes [4] [5] [6] [7] [15] [16] [17] [18] [19] [20] [21] [22] (Table 3) . Studies using rat models of C. albicans airway colonization found increased levels of inflammation and prevalence of bacterial pneumonia when compared with controls. 16, 20 Subsequent clinical studies by Hamet and colleagues and Azoulay and colleagues showed associations between Candida colonization of the respiratory tract and longer duration of mechanical ventilation, increased length of ICU and hospital stay, and increased risk of VAP in mechanically ventilated immunocompetent patients. 4, 5 Similar studies conducted in immunocompromised patients have shown that multicolonization of the oropharynx and gastrointestinal tract is associated with an increased risk of invasive Candidiasis 18, 24 and decreased short-term survival. 7 In addition, a small Dutch study identified a polymorphism in the Dectin-1 gene, which was associated with increased susceptibility to fungal infections in HSCT recipients. 25 Subsequent studies have shown a significant association between Candida colonization and the development of acute GVHD in allogeneic HSCT recipients who had Dectin-1 mutations. 26, 27 To date, no study has been able to establish whether Candida colonization is a marker of disease severity or is capable of being indirectly pathogenic.
Despite a large body of literature showing a negative relationship between Candida colonization of the respiratory tract and patient outcomes, the question of whether to treat Candida colonization remains a clinical conundrum. The benefits of prophylactic azoles for the prevention of invasive fungal infections in high-risk HSCT patients has been well documented 28, 29 ; however, studies assessing the utility of colonization eradication in both immunocompetent and immunocompromised patients are lacking. To date, 2 retrospective studies of mechanically ventilated ICU patients with Candida colonization have shown conflicting results: one study reported that the use of antifungal therapy was associated with significantly reduced development of Pseudomonas aeruginosa pneumonia, while another study found that patients treated with antifungal therapy had higher in-hospital mortality and pneumonia rates. 30, 31 A prospective, multicenter, noninterventional study conducted in Spain and Italy found that antifungal drugs were more likely to be prescribed in the setting of Candida colonization, but their use did not alter outcomes. 32 Unfortunately, interpretation of the above studies is limited by their noninterventional design and the presence of treatment bias. Designed as a pilot trial for feasibility, the CANTREAT trial is the only prospective study undertaken to better elucidate the effects of antifungal treatment. 33 The study randomized 89 critically ill adults with suspected VAP and concurrent Candida colonization to a placebo-controlled design of antifungal therapy. This study did not find any differences in inflammatory markers or hospital mortality between the treatment and placebo groups, and was discontinued prematurely due to slow enrollment, leading the authors to conclude that a larger trial could not be supported. To our knowledge, no further prospective trials exploring this question have been undertaken. Resultantly, no clear guidelines for the handling of respiratory tract colonization with Candida exist.
Our study has several limitations. The limited sample size of our study prohibited us from performing extensive multivariate analysis, with only 27 of 515 (5.2%) of BALs positive for Candida species In addition, no data were available on A B FIGURE 1. Candida isolation from the respiratory tract is associated with increased mortality in immunocompromised patients. A, When compared with subjects from whom only nonpathogenic fungi were isolated (Candida-negative group), those who were culture positive for Candida had significantly increased mortality (P = 0.04). B, There was no statistical difference in mortality between subjects in whom a pathogenic fungus was cultured (eg, Aspergillus, Pneumocystis, Mucor, etc.) and those in whom a Candida species was cultured (P = 0.24).
cause of death for patients who died. Even so, this is one of the largest studies to date of HSCT recipients. Another limitation of our study was the potential for patient bias, in which patients too sick to undergo bronchoscopy were not available for analysis, either due to the severity of their pulmonary dysfunction or other clinical features that precluded bronchoscopy. This population of patients would presumably have even higher rates of Candida colonization and worse outcomes. 34 Finally, the frequency of Candida colonization in our HSCT cohort was significantly lower than previously reported studies, likely due to the routine use of antifungal prophylaxis in the study population. 35 Although our study showed worse outcomes in those with Candida isolated from BAL, it is possible that Candida is a surrogate marker of disease severity or a confounding variable in the presence of other conditions such as GVHD or other infection. As such, the observations reported in this study do not support adding antifungal therapy for treatment of Candida in the respiratory tract.
CONCLUSIONS
We now report the incidence of Candida species. colonization in the respiratory tract of a heterogenous population of immunocompromised patients. Our study adds to the growing body of evidence that calls into question whether Candida colonization of the respiratory tract is truly the innocent bystander we have long considered it to be. While there is certainly no evidence at this stage to recommend antifungal treatment for colonization, we believe our findings should encourage further, large-enrollment, prospective clinical studies examining the role of Candida colonization as a cofactor for disease progression or as a biomarker for disease severity, particularly in an immunocompromised population.
